Skip to main content

Advertisement

SpringerLink
Log in

Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Use of targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer has led to improvements in survival. Furthermore, neoadjuvant chemotherapy (NAC) with dual HER2 agents demonstrated improved pathological complete response (pCR) rates. With these data, and with US FDA approval in September 2013 of pertuzumab in the neoadjuvant setting, we hypothesized that the use of NAC for early-stage HER2-positive patients is increasing.

Methods

With Institutional Review Board approval, we reviewed 267 patients with 268 clinical T1 and T2 HER2-positive tumors treated from October 2008 to September 2014. We compared treatment in the early (October 2008–September 2013) to recent (October 2013–September 2014) periods. Statistical analysis was performed using Chi square tests.

Results

Mean patient age was 59 years. Clinical T stage included 6 (2 %) T1mic, 11 (4 %) T1a, 41 (15 %) T1b, 95 (35 %) T1c, and 115 (43 %) T2. Targeted therapy included combinations of trastuzumab, lapatinib, pertuzumab, and neratinib. NAC use increased from 53/219 (24.2 %) in the early group to 19/49 (38.8 %) in the recent group (p = 0.04). Forty-two percent (8/19) of patients in the recent group received neoadjuvant pertuzumab versus 0/53 in the early group (p < 0.0001). More clinically node-negative (cN0) patients received NAC in the recent (12/41, 29.3 %) versus early (20/167, 12.0 %) period (p = 0.01). For T1 tumors, the use of NAC more than doubled between the two time periods (5.6–17.2 %; p = 0.06), while NAC use increased from 48 to 70 % for T2 tumors (p = 0.08). The overall pCR rate after NAC was 48.6 % (35/72).

Conclusions

NAC for HER2-positive breast cancer patients is increasing. Most striking was a substantial increase in NAC for patients with T1 tumors and cN0 disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2):309–18.

    Article  CAS  PubMed  Google Scholar 

  2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  CAS  PubMed  Google Scholar 

  3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): breast cancer. Fort Washington: National Comprehensive Cancer Network; 2015.

    Google Scholar 

  4. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  5. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.

    Article  CAS  PubMed  Google Scholar 

  6. Siegel RL, Miller KD, Jemal A. Cancer statistics 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  7. US FDA. FDA approves Perjeta for neoadjuvant breast cancer treatment. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm. Accessed 10 Apr 2015.

  8. American Joint Committee on Cancer (2010) Breast cancer staging. Cancer staging manual 7. American Joint Committee on Cancer, New York.

    Book  Google Scholar 

  9. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2012;365(9472):1687–717.

    Google Scholar 

  10. McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.

    Article  CAS  PubMed  Google Scholar 

  11. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol. 1997;15(7):2483–93.

    CAS  PubMed  Google Scholar 

  12. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2006;24(13):2019–27.

    Article  CAS  PubMed  Google Scholar 

  13. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, De Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40.

    Article  CAS  PubMed  Google Scholar 

  14. Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.

    Article  Google Scholar 

  15. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135–44.

    Article  CAS  PubMed  Google Scholar 

  16. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter TM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021–8.

    Article  CAS  PubMed  Google Scholar 

  18. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700–6.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Fehrenbacher L, Capra A, Quesenberry Jr C, Fulton R, Shiraz P, Habel L. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014;32(20):2151–8.

    Article  PubMed  Google Scholar 

  21. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142–50.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Disclosure

None.

Author information

Authors and Affiliations

  1. Department of Surgery, Mayo Clinic, Rochester, MN, 55905, USA

    Zahraa Al-Hilli MD, Judy C. Boughey MD & Tina J. Hieken MD

  2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

    Tanya L. Hoskin MS & Courtney N. Heins BS

Authors
  1. Zahraa Al-Hilli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judy C. Boughey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tanya L. Hoskin MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Courtney N. Heins BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tina J. Hieken MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina J. Hieken MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al-Hilli, Z., Boughey, J.C., Hoskin, T.L. et al. Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors. Ann Surg Oncol 22, 3369–3375 (2015). https://doi.org/10.1245/s10434-015-4718-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4718-6

Keywords

Search

Navigation